

參考文獻

1. Adrends MJ, Wyllie AH. Apoptosis: mechanism and roles in pathology. *Int Rev Pathol.* 1991; 32: 223-254.
2. Chung JG. Effects of Butylated Hydroxyanisole(BHA) and Butylate Hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. 1999; 51: 202-210.
3. Hu L, Chen Z, Xie Y. New triterpenoid saponins from *Gynostemma pentaphyllum*. *J Nat Prod* 1996; 59: 1143-5.
4. Fang ZP, Zeng XY. Structure of Gypenosides A from *Gynostemma pentaphyllum Makino*. *Yao Hsueh Pao Acta Pharmaceutia Sinica* 1996; 31: 680-3.
5. 王玉琴、張秋菊、徐世明：絞股藍皂？的抗腫瘤作用，*中西醫結合雜誌* 1988；8（5）：286-287.
6. 婁振嶺、陳偉民、馬麗萍：絞股藍多糖對腫瘤細胞的抑制作用，*河南醫科大學學報* 1996；31（1）：87-88.
7. 王志潔、李新志、程井辰：絞股藍抑制艾氏腹水癌生長的免疫機能，*腫瘤* 1990；10（6）：246-249.
8. 樑軍、湯小芳、魏小龍：絞股藍總皂對 Lewis 肺癌荷小鼠腫瘤生長及免疫功能的影響，*藥學實踐雜誌* 1999；17（5）：179-281.
9. 陳葳、李廣元：絞股藍總皂？對體外培養肝癌細胞核酸和蛋白質合成的影響，*西安醫科大學學報* 1993；14（2）：41-42.
10. 金梅、薛祥驥：絞股藍提取液對人類直腸腺癌細胞系的影響，*現代應用藥學* 1992；9（2）：49-52.
11. 謝志忠、曹建國、黃宏林、朱炳陽、周軍民、劉潔衡、庾勤慧、唐小卿：絞股藍總皂？及化療藥合用對體外培養慢性粒細胞性白血急性變病人癌細胞增殖的影響，*衡陽醫學院學報* 1998；26（1）：10-12.
12. 韓明權、劉嘉湘、高虹：24 味中藥對人肺腺癌細胞核酸和蛋白質及細胞周期的影響觀察，*中國中西醫結合雜誌* 1995；15（3）：147-149.
13. 劉華、司履生：絞股藍總皂？對體外培養肺癌細胞的抑制作用，*西安*

- 醫科大學學報 1994 ; 15 (4) : 346-348.
14. 閻軍峰、李金榮、胡傳真、劉剛：絞股藍總皂？對體外培養人口腔鱗癌頸淋巴結轉移癌細胞抑制作用的研究，臨床口腔醫學雜誌 1998 ; 14 (3) : 140-141.
 15. Chen JC, Chung JG, Chen LD. Gypenoside induces apoptosis in human Hep3B and HA22T tumor cells. *Cytobio.* 1999 ; 100 (393) : 37-48.
 16. Couch DB. Carcinogenesis: Basic principles. (Review) *Drug and Chemical Toxicology.* 1996; 19(3): 133-148.
 17. Yamagiwa K., Ichikawa K. Experimentelle studie uber die pathogenese der epithelial-geschwulste. *Mitteilungen Med. Facultat Kaiserl, Univ. Tokyo.* 1915; 15 : 295.
 18. Kennaway EC. The identification of a carcinogenic compound in coal-tar. *British Medical journal.* 1955; 2: 749-752.
 19. Acad Sin. Preliminary Surverys Cancer Institute, Department of Epidemiology, Chinese Academy Medical Sciences on the epidemiology factor of esophageal cancer in China. *Cancer Treat.* 1977; 2: 85.
 20. Selkrik JK, Maccleod MC. Chemical carcinogenesis: Nature's metabolic mistake. *Bioscience.* 1982; 32: 601-605.
 21. Adamson R., Gustofsson JA, Wakabayashi K., Yamazoe Y. Heterocyclic amines in cooked foods. *Proc. 23rd Int. pp. 1-360.* Princess Takamatsu Cancer Research Fund, Princeton Scientific, Princeton, NJ, 1995.
 22. Ferguson RJ, Doll MA, Rustan TD, Hein DW. Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the Syrian hamster. *Pharmacogenetics.* 1996; 6(1): 55-66.
 23. Ho CC, Lin TH, Chung JG, Levy GN, Weber WW. Kinetics and acetyl CoA: Arylamine N-acetyltransferase from rapid and slow acetylator frog tissue. *Drug metabolism and disposition.* 1996; 20: 137-143.
 24. Chung JG, Kuo HM, Ho CC, Levy GN, Weber WW. Kinetics and characterization of arylamine N-acetyltransferase from *Anisakis simplex*.

- Cancer letters. 1996; 106: 1-8.
25. (明)朱橚, 究荒本草, 臺灣商務印書館, 臺北 1967; p11.
 26. 陳建國: 絞股藍與其混淆品烏薺莓的本草考釋, 中草藥 1990; (9): 40-42.
 27. 邱年永、張光雄: 原色臺灣藥物植物圖鑑(2), 南天書局, 臺北 1986; p233.
 28. 歸筱銘、陳曉亮、王政峰: 福建絞股藍資源的質量評價研究, 福建中醫藥 1989; 20(6):30-31.
 29. 覃德海: 絞股藍及其相似植物的鑒別, 廣西中醫藥 1988; (3): 39.
 30. 章謙、邱方龍: 絞股藍中總皂? 含量及其提取率研究, 中國中藥雜誌 1989; (9): 39.
 31. 李若存、徐華雄、李岳: 絞股藍中氨基酸及微量元素的研究, 中國中藥雜誌 1989; (1): 41-42.
 32. 黃初升: 廣西絞股藍的微量元素測定, 廣西中醫藥 1988; (3):40.
 33. 任茜: 絞股藍多糖成分的初步分析, 西北藥學雜誌 1989; (4)3: 22-24.
 34. 方乍浦: 絞股藍中黃酮? 有機酸的分離和鑒定, 中國中藥雜誌 1989; (1): 36-38.
 35. 何勝洪: 絞股藍總皂? 對體外癌細胞的抑制作用, 武漢市醫學科研 1990; (1):12-14.
 36. 季暉: 絞股藍及其複方對家蠅的延壽作用研究, 中國藥理與臨床 1990; 6(4): 17-19.
 37. 徐本: 股藍及其複方的抗衰老實驗研究, 中成藥 1989; (5):29-30.
 38. 周壽然: 絞股藍抗衰老藥效的實驗研究, 中成藥研究 1988; (3): 25.
 39. 黃靜茹、張美仙、林密道、呂安寧: 複方絞股藍袋泡茶, 絲瓜葉對小鼠過氧化脂質的影響, 福建中醫藥 1990; 21(3): 34.
 40. 劉曉松、黃仁彬: 廣西絞股藍總皂? 的藥理研究, 中成藥 1989; (8): 27-29.
 41. 戴漢云、孟慶玉、朱捍國: 絞股藍總皂? 對各種脂蛋白的影響, 中草藥 1989; (4): 28-29.
 42. 鄭源龐: 絞股藍沖劑治療高脂血症 42 例臨床初步觀察, 中藥藥理與

- 臨床 1990; 6(4): 43-44.
43. 林松洲：食物與癌症，豪峰出版社，台北 1993; p.303 .
 44. Hoffman D, Masuada Y and Wynder ELL. Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. *Nature* 1969; (221): 255-256.
 45. Kuller H, Garfinkle L, Coreo P, Haley N, Haffman D, Preston-Martin S Sander D. Contribution of passive smoking to respiratory cancer. *Environ Health Perspect.* 1986; (70): 57-69.
 46. Greenberg ER, Barron JA. Prospects for preventing colorectal cancer death. *Jnatl Cancer Inst (editorial).* 1993; 85: 1182-1184.
 47. Lower G.M. Concepts in causality: Chemically induced human urinary bladder cancer. *Cancer.* 1982; 49: 1056-1066 .
 48. Weber WW. The acetylator genes and drug response. Oxford University press New York 1987.
 49. Levy GN, Chung JG, Weber WW. 2-aminofluorene metabolism and DNA adduct formation by mononuclear leukocytes from rapid and slow acetylator mouse strain. *Carcinogenesis.* 1994; (15): 353-357.
 50. Levy GN. DNA-carcinogen adducts in circulating leukocytes as indicators of arylamine carcinogen exposure. *Fundam Appl Toxicol.* 1993; (21): 23-30.
 51. Levy GN, Weber WW. 2-Aminofluorene DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. *Carcinogenesis.* 1992; (13): 159-164.
 52. Chung JG, Levy GN, Weber WW. Distribution of 2-aminofluorene and p-aminobenzoic N-acetyltransferase activity in tissue of C57b1/6j rapid and B6 A-Nats slow acetylator congenic mice. *Drug metabolism and disposition.* 1993; (21): 1057-1063.
 53. Hein DW, Omichinski JG, Brewer JA, Weber WW. A unique pharmacogenetic expression of the N-Acetylation polymorphism in the inbred hamster. *J Pharmacol Exp Ther.* 1982; (220): 8-15.
 54. Juberg DR, Bond JT, Weber WW. N-acetylation of aromatic amines:

- genetic polymorphism in inbred rat strains. *Pharmacogenetics*. 1991; (1): 50-57.
55. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. *Arch Biochem Biophys*. 1993; (301): 71-76.
56. Weber WW, Micelli J, Hears DJ, Drummond S. N-acetylation of drugs: Pharmacogenetic studies in rabbits selected for their acetylator characteristic. *Drug Metab Dispos*. 1976; (4): 94-101.
57. Hares DJ, Weber WW. Multiple N-acetyltransferase and drug metabolism, tissue distribution, characterization and significance of mammalian N-acetyltransferase. *Biochem J*. 1973; 132: 519-528.
58. Hein DW, Eustan JD, Furman EJ, Martin WJ. Extrahepatic expression of the N-acetylation polymorphism toward arylamine carcinogens in tumor target organ of an inbred rat model. *J Pharmacol Exp Ther*. 1991; 258: 232-236.
59. Glowinski IB, Weber WW. Biochemical characterization of genetically variant aromatic amine N-acetyltransferase in A/J mice. *J Biol Chem*. 1982; 257: 143-147.
60. Ho CC, Lin TH, Chung JG, Levy GN, Weber WW. Kinetics of acetyl CoA: Arylamine N-acetyltransferase from rapid and slow acetylator frog tissue. *Drug metabolism and disposition*. 1996; 20: 137-143.
61. Chung JG, Kuo HM, Ho CC, Levy GN, Weber WW. Kinetics and characterization of arylamine N-acetyltransferase from *Anisakis aimlex*. *Cancer Letters*. 1996; 106: 1-8.
62. Fang SH, Chung JG, Levy GN, Weber WW. *Candida albican* arylamine N-acetyltransferase: Kinetics and characterization. *Toxicol Lett*. 1997.
63. Chang FC. 2-aminofluorene metabolism by human digest system bacteria. Master Thesis 1996.
64. Chung JG, Wang HH, Lo HH, Chang SS, Wu LT, Lee JH, Hung CF. Evidence for arylamine N-acetyltransferase activity in the bacteria

- Helicobacter pylori*. Toxicol Lett. 1997; 91: 63-71.
65. Chung JG, Lee JH, Ho CC, Lai JM, Hung CF, Huan SC. A survey of arylamine N-acetyltransferase in common fruits and vegetables. Journal of Food Biochemistry. 1997; 20: 481-490.
66. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferase: a comparison of liver isozymes and expressed product of two cloned genes. Mol Pharmacol. 1991; 39: 184-191.
67. Smith G, Stanley LA, Strang, RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Survey. 1995; 25: 27-35.
68. Grant DM, Blum M. Meyer, UA. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res. 17: 3978-3986.
69. Coroneos E, Sim E. Arylamine N-acetyltransferase activity in human cultured cell lines . Biochem J. 1993; 294: 481-486.
70. Miller EC, Miller JA. Search for the ultimate chemical carcinogens and their reaction with cell macromolecules. Cancer 1981; 47: 2327-2345.
71. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta. 1988; 948: 37-66.
72. Weber WW, Levy GN, Hein DW. Acetylation “ Conjugation Reactions in Drug Metabolism” (G.J. Mulder, ed.) Taylor and Francis, London, 1990; 163-191.
73. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev. 1985; 37: 25-29.
74. Einisto P, Watanabe M, Ishidate M Jr. Normi T. Mutagenicity of 30 chemicals in *Samonella Typhimurium* strains possessing different nitroreductase or O-acetyltransferase activities. Mutation Research. 1991; 259(1): 95-102.
75. Salti GI, Grewal S, Mehta RR, Das TK, Gupta AW, Boddie Jr, AI Constantino. Genistein induces apoptosis and topoisomerase II-mediated

- DNA breakage in colon cancer cells. *European Journal of Cancer*. 2000; (36): 796-802.
76. Chinthalapally V Rao, Toshihiko Kawamori, Rachid Hamid, Bandaru S Reddy. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. *Carcinogenesis*. 1999; 20(4): 641-644.
77. Weber WW, Hein DW. N-Acetylation pharmacogenetics. *Pharmacol Rev*. 1985; (37): 25-79.
78. Chen JC, Chung JG, Chen LD: Gypenosides induces apoptosis in human Hep3B and HA22T tumor cells. *Cytobios*. 1999; 100(393): 37-48.
79. Takahiko Katoh, Robert Boissy, Naoki Nagata, Kyoko Kitagawa, Yusuke Kuroda, Hideaki Itoh, Toshihiro Kawamoto and Douglas A. Bell : Inherited polymorphism in the N-acetyltransferase1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. *Int. J. Cancer* : 2000; 85: 46-49.
80. Blum M, Grant DM, Demierre A and Meyer VA : N-aetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltrans in liver of slow acetylator raggits, *Proceedings of the National Academa of sciences of the United States of America*. 1989,86(23):9554-9557.
81. Selkrik JK. And Macleod MC.: Chemical carcinogenesis: Nature' s metabolic mistake. *Bioscience*, 1982; 32:601-605.
82. Debiec-Rychter M., Tada M., Poiruer MC. And Wang CY. DNA adduct formation in human and rat mammary epithelium by N-hydroxyderivatives of 2-aminofluorene and 4-aminobiphenyl 3 Teratogenesis, *Carcinogenesis, & Mutagenesis* 1998; 18(1):35-39.
83. Hein DW. : Acetylator genotype and arylamine induced carcinogenesis. *Biochimica et biophysica Acta* .1988; 948:37-66.
84. Wick MJ, Hanna PE. Bioactivation of N-arylhydroxamine acids by rat

- hepatic N-acetyltransferase: detection of multiple enzyme forms by mechanism based on activation. *Biochem. Pharmacol.* 29:991-1003.
85. Wynder EL, Kajitani T, Ishidawa S, Dodo H and Takano A. Environmental factors in cancer of colon and rectum. *Cancer (Phila)*, 1969,23:1210-1220.
 86. Einisto P, Watanabe M, Ishidate M and Nohmi T. Mutagenicity of 30 chemicals in *S. typhimurium* possessing different nitroreductase or O-acetyltransferase activities. *Mutation Res.* 1991;259:95-102
 87. Srivastava AK and Wiebel FJ: Arylamine N-acetyltransferase activities in cell lines of mouse, rat, hamster and man differing in their sensitivity to 1,6 di-nitropyrene 1990; 54 (1) : 71-76.
 88. Zhou Z, Wang Y, Zhou Y: The effect of *Gynostemma pentaphyllum* Makino (GP) on carcinogenesis of the golden hamster cheek pouch induced by DMBA. *Zhonghua Kou Qiang Yi Xue Za Zhi* 1996; 31: 267-270.
 89. Chung JG: Effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. *Toxicol Sci* 1999; 51: 202-210.
 90. Larsen GL. Deconjugation of biliary metabolites by microfloral β -glucuronidase, sulphatase and cysteine conjugate β -lyase and their subsequent enterohepatic circulation. In: I. Rowland (ed.), *Role of gut flora in toxicity and cancer*, 1988; pp 79-107 London: Academic Press.
 91. Kinouchi T, Kataoka K, Miyanishi K, Akimoto S, Ohnishi Y. Biological activities of the intestinal microflora in mice treated with antibiotics or untreated and the effects of the microflora on absorption and metabolic activation of orally administered glutathione conjugates of K-region epoxides of 1-nitropyrene. *Carcinogenesis (Lond.)*. 1993; 14: 869-874.
 92. Okumuro F, Uedo O, Kitamura S, Tatsumi K. N-acetyltransferase and N-formation of carcinogenic arylamines and related compounds in dogs.

- Carcinogenesis.1995; 1: 71-76.
93. Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ. Shikonin, an ingredient of *Lithospermum erythrorhizon* induced apoptosis in HL-60 human premyelocytic leukemia cell line. *Planta Medica* 1999; 65: 532-535.
 94. Fujii N, Yamashita Y, Arima Y, Nagashima M, Nakano H. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. *Antimicrob Agent Chemother* 1992; 36: 2589-2594.
 95. Kamei R, Kitagawa Y, Kadokura M, Hattori F, Hazeki O, Ebina Y, Nishihara T, Oikawa S. Shikonin stimulates glucose uptake in 3T3-L1 adipocytes via an insulin-independent tyrosine kinase pathway. *Biochem Biophys Res Commun* 2002; 292: 642-651.
 96. Lu Q, Liu W, Ding J, Cai J, Duan W. Shikonin derivatives: synthesis and inhibition of human telomerase. *Bioorg Med Chem Lett* 2002; 20: 1375-1378.
 97. Zubay GL, WW Parson, DE Vance. *Principles of biochemistry*. 1955, pp. 135-153. Wm. C. Brown Publishers.
 98. Bellman S, Troll W, Teebor G, Mukai F. The carcinogenic and mutagenic properties of N-hydroxy-aminonaphthalenes. *Cancer Research* 1968; 28: 535-542.
 99. Enomoto M, Lotlikar P, Miller JA, Miller EC. Urinary metabolites of 2-acetylaminofluorene and related compounds in the rhesus monkey. *Cancer Research* 1962; 22: 1336-1342.
 100. Irving CC. N-hydroxylation of 2-acetylaminofluorene in the rabbit. *Cancer Research* 1962; 22: 867-873.
 101. Kadlubar FF, Unruh LE, Flammang TJ, Sparks D, Mitchum RK, Mulder GJ. Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretion. *Chemico-Biological Interactions* 1981; 33(2-3): 129-147.

102. Lynn RK, Garvie-Gould CT, Milam DF, Scott KF, Eastman CL, Ilias AM, Rodgers RM. Disposition of the aromatic amine, benzidine, in the rat: characterization of mutagenic urinary and biliary metabolites. *Toxicology and Applied Pharmacology* 1984; 72: 1-14.
103. Miller JA, Wyatt CS, Miller EC, Hartmann HA. The N-hydroxylation of 4-1cetylaminobiphenyl by the rat and dog and the strong carcinogenicity of N-hydroxy-4-acetylaminobiphenyl in the rat. *Cancer Research* 1961; 21: 1465-1473.
104. Poirier LA, Miller JA, Miller EC. The N- and ring-hydroxylation of 2-acetylaminofluorene and the failure to detect N-acetylation of 2-acetylaminofluorene in the dog. *Cancer Research* 1963; 23: 790-800.
105. Poupko JM, Hearn WL, Radomski JL. N-Glucuronidation of N-hydro aromatic amines: a mechanism for their transport and bladder specific carcinogenicity. *Toxicology and Applied Pharmacology* 1979; 50: 479-484.
106. Radomski JL, Conzelman GM, Rey AA, Brill E. N-Oxidation of certain aromatic amines, acetamides, and nitro compounds by monkeys and dogs. *Journal of the National Cancer Institute* 1973; 50(4): 989-995.
107. Weisburger JH, Grantham PH, Vanhorn E, Steigbigel NH, Rall DP, Weisburger EK. Activation and detoxification of N-2-fluorenyl-acetamide in man. *Cancer Research* 1964; 24: 475-479.
108. Ching YW, Kim Z, Lee MS, Katsumi I. Production of urothelial tumors in the heterotopic bladder of rats by instillation of N-glucuronosyl or N-acetyl derivatives of N-hydroxy-2-aminofluorene. *Cancer Research* 1987; 47: 3406-3409.
109. Irving CC, Wiseman R. Jr. Studies on the carcinogenicity of the glucuronides of N-hydroxy-2-acetylaminofluorene and N-2-fluorenylhydroxylamine in the rat. *Cancer Research* 1971; 31: 1645-1648.
110. Stark KL, Harris C, Juchau MR. Modulation of the embryotoxicity and

cytotoxicity elicited by 7-hydroxy-2-acetyl-aminofluorene and acetaminophen via deacetylation. *Toxicology and Applied Pharmacology* 1989; 97: 548-560.

111. Chung JG, Wu LT, Chang SH, LO HH, Hsieh SE. Inhibitory actions of berberine on arylamine N-acetyltransferase activity in strains of *Helicobacter pylori* from peptic ulcer patients. *International Journal of Toxicology* 1999; 18: 35-40.